Evaluating BP1002 for patients with relapsed or refractory acute myeloid leukemia

A Phase I/Ib Study of BP1002 (a Liposomal Bcl-2 Antisense Oligodeoxynucleotide) in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

This study is testing a new treatment called BP1002 to see if it can help people with relapsed or refractory acute myeloid leukemia who haven't responded to other therapies.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Bio-Path Holdings, Inc. (Industry-sponsored)
• Drugs / interventions: chemotherapy, immunotherapy
• Locations: 4 sites (La Jolla, California and 3 other locations)
• Trial ID: NCT05190471 on ClinicalTrials.gov

What this trial studies

This clinical trial investigates the safety and tolerability of BP1002, a liposomal Bcl-2 antisense oligonucleotide, in patients suffering from refractory or relapsed acute myeloid leukemia (AML). The study consists of a dose escalation phase to determine the maximum tolerated dose and a dose expansion phase where BP1002 will be assessed in combination with decitabine. The trial aims to evaluate the pharmacokinetics, pharmacodynamics, and potential anti-leukemic effects of BP1002. Participants must have previously failed standard treatments for AML.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with histologically confirmed refractory or relapsed AML who have not responded to existing therapies.

Not a fit: Patients who are not eligible for decitabine therapy or have not failed previous treatments for AML may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with limited alternatives for refractory or relapsed AML.

How similar studies have performed: While this approach is novel, similar studies targeting Bcl-2 pathways have shown promise in other hematological malignancies.

Eligibility criteria

Inclusion Criteria:

1. Adults ≥18 years of age, with histologic evidence of refractory/relapsed AML who have failed treatment with available therapies known to be active for refractory/relapsed AML
2. Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0, 1 or 2
3. For the dose expansion phase, participants with documented diagnosis of AML who are eligible for decitabine therapy
4. Participants must have adequate hepatic and renal functions as defined by:

   1. Aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 times the upper limit of normal (ULN); and
   2. Usually total bilirubin ≤ 1.5 ULN. In specific cases the PI may request a waiver of this requirement with medical justification and agreement with the medical monitor and Bio-Path Holdings. And;
   3. Estimated creatinine clearance of at least 60 mL/min. These estimations are calculated using the Cockcroft-Gault equation.
5. Female participants of childbearing potential must agree to use an acceptable method of birth control (i.e. a hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide or abstinence) for the duration of the study and for at least 6 months after the last dose of study drug or decitabine
6. Male participants must agree to use an acceptable method of contraception for the duration of the study
7. Recovered from the effects of any prior surgery, radiotherapy, or antineoplastic treatment (with the exception of alopecia), based on Investigator assessment
8. Participants must be willing and able to provide written informed consent

Exclusion Criteria:

1. Active non-hematologic or lymphoid malignancy other than AML treated with immunotherapy, targeted therapy or chemotherapy within the previous 12 months
2. Known, active leptomeningeal leukemia requiring intrathecal therapy. NOTE: Participants with a history of CNS disease may be allowed to participate based on at least 1 documented, negative spinal fluid assessment within 28 days prior to Screening
3. Isolated potentially treatable extramedullary leukemia without also meeting bone marrow criteria for acute leukemia (for AML usually ≥ 5% blasts in BMA or biopsy). Participants may have leukemia with lower blast counts (Döhner 2017). Bio-Path Holdings and Investigator concurrence required.
4. Acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) PML-RARA
5. Chronic myeloid leukemia in any phase
6. Receipt of any anti-cancer therapy within 14 days prior to C1D1, with the exception of hydroxyurea or leukapheresis
7. Participants may not be receiving any other investigational agents
8. Female participants who are pregnant or breast-feeding
9. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
10. Participants with human immunodeficiency virus (HIV) infection who have CD4+ T-cell counts \< 350 cells/mcL or with clinically active hepatitis B or C infection
11. History of any hypersensitivity to hypomethylating agents, unless reaction is deemed irrelevant to the study by the Investigator and Medical Monitor
12. Unresolved toxicity higher than CTCAE Grade 1 attributed to any prior therapy or procedure, excluding alopecia
13. Presence of concurrent conditions that, in the opinion of the Investigator and/or Medical Monitor, may compromise the participant's ability to tolerate study treatment or interfere with any aspect of study conduct or interpretation of results. This includes, but is not limited to, unstable or uncontrolled angina, New York Heart Association (NYHA) class III or IV congestive heart failure, uncontrolled and sustained hypertension, clinically significant cardiac dysrhythmia or clinically significant baseline ECG abnormality (e.g., QTcF \>470 msec)
14. Within the past 6 months, has had any of the following: myocardial infarction, unstable angina pectoris, coronary/peripheral artery bypass graft, cerebrovascular accident or transient ischemic attack
15. Uncontrolled seizure disorder (i.e., seizures within the past 2 months)
16. Unable or unwilling to communicate or cooperate with the Investigator or follow the protocol for any reason

Where this trial is running

La Jolla, California and 3 other locations

• Scripps Green Hospital — La Jolla, California, United States (Recruiting)
• UCLA Medical Center — Los Angeles, California, United States (Recruiting)
• Weill Cornell Medical College - NewYork-Presbyterian Hospital — New York, New York, United States (Recruiting)
• MD Anderson Cancer Center — Houston, Texas, United States (Recruiting)

Study contacts

• Principal investigator: Gail J Roboz, MD — Weill Cornell Medical College - New York-Presbyterian Hospital
• Study coordinator: Michael Hickey

Conditions Acute Myeloid Leukemia, in Relapse; Acute Myeloid Leukemia Refractory